---

Correction to Lords Written Answer

My honourable friend the Parliamentary Under-Secretary of State, Department of Health (Anne Milton) has made the following Written Ministerial Statement. In answering a parliamentary question from the honourable Member for Worthing West, (Sir Peter Bottomley), (Official Report, 1 March 2011, col. 379w), I provided details of the protection afforded by the two HPV vaccines licensed for use in the United Kingdom. These are Cervarix manufactured by GlaxoSmithKline and Gardasil manufactured by Sanofi Pasteur MSD. However my answer also referred to the cross-protection afforded by Cervarix, but I omitted to provide equivalent information on Gardasil and in doing so may have presented an incomplete view to the House. In the case of Gardasil, the Summary of Product Characteristics states that, "““statistically significant efficacy against disease was demonstrated against HPV types … related to HPV 16 (primarily HPV 31) whereas no statistically significant efficacy was observed for HPV types … related to HPV 18 (including HPV 45). For the 10 individual HPV types, statistical significance was only reached for HPV 31.””" To ensure clarity and completeness of information about the efficacy of both vaccines, I have placed copies of their Summary of Product Characteristics in the Library. Copies of the SPCs for Cervarix and for Gardasil are available for honourable Members from the Vote Office and for noble Lords from the Printed Paper Office. They can also be seen at: www.medicines.org.uk/emc/medicine/20204/SPC/Cervarix/ www.medicines.org.uk/EMC/medicine/19016/SPC/GARDASIL/